NASDAQ:ATOS Atossa Genetics (ATOS) Stock Price, News & Analysis $1.81 -0.09 (-4.74%) Closing price 04:00 PM EasternExtended Trading$1.81 +0.00 (+0.06%) As of 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Atossa Genetics Stock (NASDAQ:ATOS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Atossa Genetics alerts:Sign Up Key Stats Today's Range$1.79▼$1.9250-Day Range$1.90▼$2.9152-Week Range$1.70▼$14.85Volume42,714 shsAverage Volume111,283 shsMarket Capitalization$18.06 millionP/E RatioN/ADividend YieldN/APrice Target$20.33Consensus RatingModerate Buy Company Overview Atossa Therapeutics, Inc., formerly known as Atossa Genetics, is a clinical-stage biopharmaceutical company focused on developing treatments for breast cancer. The company is based in Seattle, Washington. Its lead investigational drug candidate is (Z)-endoxifen, a form of endoxifen, which is an active metabolite of tamoxifen. Atossa is studying the candidate in clinical programs for breast cancer, including estrogen receptor-positive disease. The company has also explored oral and topical formulations. Atossa was founded as Atossa Genetics and adopted the Atossa Therapeutics name as its focus shifted toward drug development. Its products remain investigational and are not approved for commercial use.AI Generated. May Contain Errors. Read More Atossa Genetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreATOS MarketRank™: 2.24737052323 of 5 starsAtossa Genetics scored higher than 45% of companies evaluated by MarketBeat, and ranked 375th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingAtossa Genetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAtossa Genetics has a consensus price target of $20.33, representing about 967.9% upside from its current price of $1.90.Amount of Analyst CoverageAtossa Genetics has only been the subject of 1 research reports in the past 90 days.Read more about Atossa Genetics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Atossa Genetics are expected to grow in the coming year, from ($3.75) to ($2.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atossa Genetics is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atossa Genetics is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtossa Genetics has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.85% of the float of Atossa Genetics has been sold short.Short Interest Ratio / Days to CoverAtossa Genetics has a short interest ratio ("days to cover") of 7.59.Change versus previous monthShort interest in Atossa Genetics has recently decreased by 22.93%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtossa Genetics does not currently pay a dividend.Dividend GrowthAtossa Genetics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 3 people have searched for ATOS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Atossa Genetics to their MarketBeat watchlist in the last 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Atossa Genetics insiders have not sold or bought any company stock.Percentage Held by Insiders9.80% of the stock of Atossa Genetics is held by insiders.Percentage Held by Institutions12.74% of the stock of Atossa Genetics is held by institutions.Read more about Atossa Genetics' insider trading history. Receive ATOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atossa Genetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATOS Stock News HeadlinesAtossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate UpdateNovember 10, 2026 | prnewswire.comAtossa Genetics (ATOS) Expected to Announce Earnings on WednesdayNovember 10, 2026 | americanbankingnews.comDon’t delete this, read it todayPorter Stansberry has spent more than 30 years studying the economy and financial markets, and says he has never felt pressure like this. He believes the foundations beneath our way of life have cracked. One Nobel Prize winner has warned that the force behind it threatens to divide America. Stansberry points to rising living costs, deepening division and building anger as signs. His documentary, The Final Displacement, names the force and outlines what he believes you can do about it now.November 18 at 1:00 AM | Porter & Company (Ad)Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business TodayOctober 19, 2026 | prnewswire.comAtossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher ValueOctober 9, 2026 | prnewswire.comAtossa plans shareholder stake in potential PRV proceedsSeptember 30, 2026 | msn.comAtossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review VoucherSeptember 29, 2026 | prnewswire.comAtossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of AgingSeptember 24, 2026 | prnewswire.comSee More Headlines ATOS Stock Analysis - Frequently Asked Questions How have ATOS shares performed this year? Atossa Genetics' stock was trading at $8.85 on January 1st, 2026. Since then, ATOS stock has decreased by 78.5% and is now trading at $1.9040. How were Atossa Genetics' earnings last quarter? Atossa Genetics Inc. (NASDAQ:ATOS) issued its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.86) by $0.30. When did Atossa Genetics' stock split? Atossa Genetics's stock reverse split on Monday, February 2nd 2026.The 1-15 reverse split was announced on Monday, January 26th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 30th 2026. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Atossa Genetics IPO? Atossa Genetics (ATOS) raised $6 million in an initial public offering on Thursday, November 8th 2012. The company issued 1,200,000 shares at $4.00-$6.00 per share. How do I buy shares of Atossa Genetics? Shares of ATOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Atossa Genetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atossa Genetics investors own include NIO (NIO), NVIDIA (NVDA), Ocugen (OCGN), SNDL (SNDL), Vaxart (VXRT), Tesla (TSLA) and Bionano Genomics (BNGO). Company Calendar Last Earnings11/10/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ATOS's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ATOS CIK1488039 Webatossatherapeutics.com Phone(206) 588-0256Fax206-430-1288Employees14Year Founded2009Price Target and Rating Average Price Target for Atossa Genetics$20.33 High Price Target$25.00 Low Price Target$12.00 Potential Upside/Downside+1,023.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($3.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.77 million Net MarginsN/A Pretax MarginN/A Return on Equity-117.07% Return on Assets-96.08% Debt Debt-to-Equity RatioN/A Current Ratio5.35 Quick Ratio5.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.18 per share Price / Book0.83Miscellaneous Outstanding Shares9,980,000Free Float9,001,000Market Cap$18.06 million OptionableOptionable Beta1.38 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:ATOS) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersDon’t delete this, read it todayPorter Stansberry has spent more than 30 years studying the economy and financial markets, and says he has nev...Porter & Company | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredGet your evenings backThe Instant Scanner delivers the night's qualifying setups with exact buy prices and defined exits, in minutes...Profits Run | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Genetics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Genetics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.